The technology virtualizes immunohistochemistry to deliver per-cell spatial biomarker data in minutes, with a research poster presentation slated for USCAP 2026.

ViewsML is bringing its artificial intelligence (AI)-driven virtual staining technology to the United States and Canadian Academy of Pathology (USCAP) 2026 Annual Meeting this week, showcasing a platform that predicts biomarker expression directly from routine hematoxylin and eosin (H&E) pathology images—without the need for physical immunohistochemistry (IHC).

The San Antonio conference, held March 21–26 at the Henry B. González Convention Center, serves as a stage for the company to demonstrate how its approach can generate per-cell spatial biomarker insights from standard H&E slides in minutes, a process that can otherwise take days to weeks under traditional laboratory workflows, according to a release from the company.

Virtualizing a Decades-Old Diagnostic Process

IHC is a staple of anatomic pathology, used to detect specific proteins in tissue sections and guide diagnoses and treatment decisions. The technique has remained largely unchanged for decades. ViewsML’s platform aims to modernize that process by using AI to generate the equivalent of IHC staining data directly from existing H&E images, eliminating the need to consume additional tissue or run additional laboratory tests, according to the company.

The company says it is building what it describes as the world’s first virtual biomarker library—a repository of AI-generated, per-cell spatial insights derived from routine pathology images. The approach is designed to unlock biological value from slides that laboratories have already processed, according to the release.

For clinical laboratorians managing limited biopsy material—a persistent challenge in oncology and research settings—the ability to extract new biomarker data from existing specimens without additional staining could have meaningful implications for tissue stewardship and workflow efficiency. The technology is positioned to support research, clinical trials, and patient care by accelerating access to spatial biomarker data, the company says.

Research Collaboration at USCAP

Alongside its exhibit at booth 455, ViewsML will co-present a poster with collaborators from Penn State Health Milton S. Hershey Medical Center and Dartmouth-Hitchcock Medical Center. The poster, titled “Virtual Multiplex Immunofluorescence from H&E Predicts Spatial Expression Patterns of Immune and Stromal Cells in NSCLC,” will be presented on March 24 from 1 to 4:30 pm in Hall 2.

The work focuses on non-small cell lung cancer, one of the most commonly diagnosed and studied forms of lung cancer, and examines whether the platform can accurately predict the spatial distribution of immune and stromal cell populations—data that is typically obtained through multiplex immunofluorescence staining, a more resource-intensive process.

ID 122083708 © Arindam Ghosh | Dreamstime.com

Related Links: